Study to Reduce Intravenous Exposures (STRIVE)

NCT00391482 | Completed Phase 2

• 2 other identifiers: DESPR DA0144991R01DA014499
• Study Type: interventional
• Target: 750
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this study is to determine whether a six-session, small group behavioral intervention based on "peer-volunteer activism" is effective in (1) decreasing distributive sharing of syringes and other injection paraphernalia and (2) increasing utilization of HCV-related healthcare services among HCV-infected injection drug users

Conditions

Hepatitis C; HIV Infections

Keywords

IV Drug Users; Hepatitis C Virus; Human Immunodeficiency Virus; Intervention; HIV Seronegativity

Outcome Measures

Primary Outcomes (1)

• Self-reported frequency of distributive sharing of injection and non-injection drug equipment (i.e., lending, giving or selling used needles, syringes or paraphernalia to others)

Secondary Outcomes (1)

• Alcohol use; disposal of syringes and paraphernalia; increased condom use; syringe exchange program use; readiness for HCV therapy and drug use cessation; and discussing HCV therapy options at a medical care visit.

Interventions

Peer Mentoring Intervention for HCV-Infected IDUs BEHAVIORAL

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• HCV antibody positive
• age between 18 and 35 years old;
• reported injection drug use in the past 6 months
• willing to provide a blood sample for liver function testing

You may not qualify if:

• HIV antibody positive
• planned on moving from city within the next 12 months;
• unable to comprehend English well enough to complete English-only assessments and group sessions

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA): lead

Study Sites (3)

Johns Hopkins University, Bloomberg School of Public Health

Baltimore, Maryland, 21205, United States

Location

New York Academy of Medicine, Center for Urban Epidemiologic Studies

New York, New York, 10029, United States

Location

Public Health Seattle & King County

Seattle, Washington, 98104, United States

Location

Related Publications (6)

• Strathdee SA, Latka M, Campbell J, O'Driscoll PT, Golub ET, Kapadia F, Pollini RA, Garfein RS, Thomas DL, Hagan H; Study to Reduce Intravenous Exposures Project. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005 Apr 15;40 Suppl 5(Suppl 5):S304-12. doi: 10.1086/427445.

  PMID: 15768339 BACKGROUND

• Campbell JV, Hagan H, Latka MH, Garfein RS, Golub ET, Coady MH, Thomas DL, Strathdee SA; STRIVE Project. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend. 2006 Feb 28;81(3):259-65. doi: 10.1016/j.drugalcdep.2005.07.005. Epub 2005 Aug 29.

  PMID: 16129567 BACKGROUND

• Golub ET, Latka M, Hagan H, Havens JR, Hudson SM, Kapadia F, Campbell JV, Garfein RS, Thomas DL, Strathdee SA; STRIVE Project. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health. 2004 Jun;81(2):278-90. doi: 10.1093/jurban/jth114.

  PMID: 15136661 BACKGROUND

• Hagan H, Latka MH, Campbell JV, Golub ET, Garfein RS, Thomas DA, Kapadia F, Strathdee SA; Study to Reduce Intravenous Exposures Project Team. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis. 2006 Mar 1;42(5):669-72. doi: 10.1086/499951. Epub 2006 Jan 20.

  PMID: 16447112 BACKGROUND

• Drumright LN, Hagan H, Thomas DL, Latka MH, Golub ET, Garfein RS, Clapp JD, Campbell JV, Bonner S, Kapadia F, Thiel TK, Strathdee SA. Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. J Hepatol. 2011 Jul;55(1):45-52. doi: 10.1016/j.jhep.2010.10.028. Epub 2010 Nov 24.

  PMID: 21145862 DERIVED

• Kapadia F, Latka MH, Hagan H, Golub ET, Campbell JV, Coady MH, Garfein RS, Thomas DL, Bonner S, Thiel T, Strathdee SA. Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE). J Urban Health. 2007 Jan;84(1):99-115. doi: 10.1007/s11524-006-9133-7.

  PMID: 17200799 DERIVED

MeSH Terms

Conditions

Hepatitis C; HIV Infections; Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Hepatitis, Viral, Human; Virus Diseases; Flaviviridae Infections; RNA Virus Infections; Hepatitis; Liver Diseases; Digestive System Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Slow Virus Diseases

Study Officials

• Steffanie A Strathdee, PhD

  Johns Hopkins University, Bloomberg School of Public Health,

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Intervention Model: PARALLEL
• Sponsor Type: NIH

Study Record Dates

• First Submitted: October 20, 2006
• First Posted: October 24, 2006
• Study Start: June 1, 2002
• Study Completion: February 1, 2005
• Last Updated: January 11, 2017

Record last verified: 2008-11

Locations

US (3)